- Short communication
- Open Access
- Published:
68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas
European Journal of Hybrid Imaging volume 4, Article number: 4 (2020)
Abstract
Purpose
Clinically non-functioning pituitary macroadenomas (NFMA) have been reported to express somatostatin receptors (SSTR), but results are inconsistent across different studies. This may be related to limited sensitivity and specificity of techniques used to date, i.e. immunohistochemistry in surgical specimens and 111In-DTPA-octreotide scintigraphy in vivo. The aim of this study was to assess SSTR expression in NFMA in vivo using 68Ga-DOTATATE PET, which offers superior sensitivity and spatial resolution as compared with planar scintigraphy or SPECT.
Methods
Thirty-seven patients diagnosed with NFMA underwent 68Ga-DOTATATE PET/CT of the head in the framework of a randomised controlled trial assessing the effect of the somatostatin analogue lanreotide on NFMA size. Individual co-registered T1-weighted pituitary MRIs were used to assess 68Ga-DOTATATE uptake (SUVmean) in the adenoma. An SUVmean of > 2 was considered positive.
Results
68Ga-DOTATATE uptake was positive in 34/37 patients (92%), with SUVmean of positive adenomas ranging from 2.1 to 12.4 (mean ± SD 5.8 ± 2.6).
Conclusions
This is the first report of 68Ga-DOTATATE PET performed in NFMA patients, demonstrating in vivo SSTR expression in the vast majority of cases. The high positivity rate when compared with results obtained with 111In-DTPA-octreotide scintigraphy probably reflects the superior sensitivity of PET imaging.
Trial registration
Netherlands Trial Register, NL5136, registered on 18 August 2015; EudraCT, 2015-001234-22, registered on 10 March 2015, https://eudract.ema.europa.eu/
Introduction
Pituitary adenomas are benign tumours of the pituitary gland and the third most common intracranial neoplasm. Around 30% are clinically non-functioning adenomas (NFA) that lack clinical and biochemical signs of hormonal activity (Even-Zohar and Greenman 2018). Due to the absence of signs related to hormonal hypersecretion, NFA usually present as macroadenomas (i.e. diameter ≥ 1 cm), causing compression of surrounding structures. Surgical resection is often incomplete, especially in the case of cavernous sinus invasion, and regrowth of residual adenoma tissue is common (Even-Zohar and Greenman 2018). Although adjuvant radiotherapy is effective in preventing tumour regrowth, its use is controversial because of long-term side effects such as hypopituitarism and neurocognitive dysfunction (Even-Zohar and Greenman 2018). This explains the ongoing interest in medical treatment, including somatostatin analogues (SSA). The rationale for this approach is the expression of somatostatin receptor (SSTR) subtypes in a varying proportion of NFA, as demonstrated by quantitative PCR and immunohistochemistry studies (Fusco et al. 2012; Ramírez et al. 2012; Gabalec et al. 2015). In vivo visualisation of SSTR expression via 111In-DTPA-octreotide planar scintigraphy or SPECT has shown increased uptake in about two thirds of patients (Fusco et al. 2012; Borson-Chazot et al. 1997). Encouraged by these findings, several open-label studies have investigated the effect of the SSA octreotide in NFA patients. Thus far, success has been modest, with tumour reduction in 12% of patients and no clear correlation with SSTR expression based on 111In-DTPA-octreotide scintigraphy results (for review, see Colao et al. 2008). However, the number of patients per study did not exceed 20, and the average follow-up period was only 6 months. One recent study with a mean follow-up of 3 years showed stable adenoma size in 81% of 26 patients, pre-selected through positive 111In-DTPA-octreotide uptake, compared with stability in 47% of 13 untreated patients that had negative uptake (Fusco et al. 2012).
In vivo evaluation of SSTR expression to predict clinical response to SSA is an attractive approach, especially since it does not require a surgical specimen and can thus be performed preoperatively. However, interpretation of pituitary adenoma uptake using planar scintigraphy/SPECT has several limitations, most importantly limited spatial resolution. PET/CT imaging with the SSA radiotracer 68Ga-DOTATATE provides better resolution and sensitivity and allows for accurate quantification of uptake within the adenoma (Bai et al. 2013; Aalbersberg et al. 2019). 68Ga-DOTATATE PET/CT could thus be superior to 111In-DTPA-octreotide scintigraphy for the assessment of SSTR expression in NFA. However, the rate of positive 68Ga-DOTATATE uptake in NFA has not been reported to date. This was the aim of the present study.
Methods
Patients
Adult patients diagnosed with a clinically non-functioning pituitary macroadenoma (NFMA) with suprasellar extension, either surgery-naive or as a postoperative remnant, were eligible for inclusion. Patients were referred by endocrinologists at hospitals in the Netherlands for inclusion at one of the participating centres (Amsterdam University Medical Centres (locations AMC and VUmc) and Leiden University Medical Centre) as part of a multicentre randomised controlled trial on the effect of lanreotide on NFMA size. NFMA diagnosis was based on neuroradiological evidence for a pituitary macroadenoma on MRI and absence of clinical and biochemical signs of hormonal overproduction. Exclusion criteria included visual field defects due to optic chiasm compression, previous radiotherapy involving the pituitary region and previous use of SSA. The study protocol was approved by the Medical Ethics Committee of the AMC and registered at the Netherlands Trial Register (NL5136) and EudraCT (2015-001234-22). All participants provided written informed consent.
Imaging
Brain PET/CT imaging (Gemini ToF, Philips Medical Systems and Biograph mCT, Siemens Healthineers) was performed at the Netherlands Cancer Institute and the Amsterdam UMC, location AMC. 68Ga-DOTATATE radiosynthesis and quality control were performed as described earlier (Aalbersberg et al. 2019). Acquisitions were obtained approximately 45 min after intravenous bolus injection of 100 MBq 68Ga-DOTATATE with 2.5–3 min per bed position. A low-dose CT scan was acquired for attenuation correction and anatomical correlation (120 kVp, 60 mAs, pitch 0.813). Pituitary MRI was performed at the referring hospital as part of standard care on a 1.5- or 3-T scanner, following a pituitary-specific protocol that includes acquisitions before and after gadolinium administration and preferably a 3D T1-weighted sequence.
Image analysis
PET/CT and MRI were co-registered using Hybrid Viewer (Hermes Medical Solutions, version 2.8.2). 68Ga-DOTATATE uptake in the adenoma was assessed on the fused PET/MR images by placement of a circular region of interest (ROI) within the adenoma on the coronal plane. The ROI covered the larger part of the adenoma diameter and was non-fixed to account for variability in adenoma size. A clear margin from normal pituitary tissue was maintained to avoid activity spillover effects from physiological pituitary uptake (Bai et al. 2013). ROI placement was performed by the same physician (TB). Within the defined ROI, the mean standard uptake value (SUVmean) was determined, which was confirmed by the same nuclear medicine physician in all patients (JB). Positive uptake was defined as an SUVmean of > 2, based on a 68Ga-DOTATATE biodistribution study in which physiological pituitary uptake always had an SUVmean of > 2 (Shastry et al. 2010).
Statistical analysis
Continuous variables are reported as mean with standard deviation (SD). Categorical variables are expressed as proportions. Data were analysed using the SPSS software (IBM SPSS Statistics, version 25).
Results
Thirty-seven NFMA patients were included between November 2015 and July 2019. Adenoma size, measured as the maximum diameter in any direction, ranged from 12 to 44 mm. Clinical characteristics and 68Ga-DOTATATE PET uptake results are summarised in Table 1. 68Ga-DOTATATE uptake was positive in 34/37 patients (91.9%), with SUVmean ranging from 2.1 to 12.4 (mean ± SD 5.8 ± 2.6). The 3 PET-negative patients had SUVmean values of 0.7, 0.8 and 1.1. There was no significant correlation between adenoma size and SUVmean (rs = 0.186, p = 0.259, Spearman’s rank correlation). Because of the small number of PET-negative patients, no statistical tests were performed on group differences. However, clinical characteristics seemed to be comparable between patients with positive and negative uptake. 68Ga-DOTATATE PET-positive and PET-negative cases are presented in Fig. 1.
Coronal T1-weighted contrast-enhanced MRI and fused PET/MR images of a 68Ga-DOTATATE PET-positive (a, b) and PET-negative (c, d) NFMA. The colour bars represent SUV. a MRI shows a pituitary macroadenoma (asterisk) located laterally in the sella with an invasion of the left cavernous sinus. b After fusion with PET, intense uptake is seen in the NFMA (SUVmean 5.7) as well as physiological uptake in the pituitary gland on the right side of the adenoma. c In this case, the largest part of the adenoma (asterisk) is located on the right side of the pituitary stalk. d The fused PET/MRI shows no uptake in the NFMA (SUVmean 1.1) and moderate physiological uptake in the pituitary gland situated on top of the adenoma
Discussion
In this study, we demonstrate positive 68Ga-DOTATATE uptake in 92% of NFMA (34/37). This positivity rate is higher than the two thirds of patients as reported earlier with 111In-DTPA-octreotide planar scintigraphy or SPECT (Fusco et al. 2012; Borson-Chazot et al. 1997). One likely explanation for this discrepancy is the superior sensitivity, higher spatial resolution and better partial volume recovery of PET (Bai et al. 2013). The limited resolution of planar scintigraphy/SPECT makes differentiation of 111In-DTPA-octreotide uptake in the adenoma from physiological uptake in the adjacent pituitary gland difficult. Most studies have therefore compared the uptake in the sellar region of patients to that of subjects without a pituitary disease, using either a visual grading system or a background-corrected uptake index to interpret results (Fusco et al. 2012). With this method, only adenomas with increased uptake as compared with the pituitary gland are considered positive. While in some cases this may lead to false positives if physiological pituitary uptake is higher than usual, a greater risk exists for false negatives when adenoma uptake is comparable to the applied limit. Additionally, in case of heterogeneous SSTR expression within an NFA, the low resolution can induce underestimation of the activity due to the partial volume effect (Borson-Chazot et al. 1997; Bai et al. 2013).
The two- to threefold higher spatial resolution of PET/CT in combination with more accurate attenuation correction makes it the preferred functional imaging modality for smaller lesions such as pituitary adenomas. Furthermore, uptake quantification with SUVs allows for a more objective evaluation. Of note, physiological uptake in the normal pituitary is also evident with 68Ga-DOTATATE PET, which hinders a straightforward assessment of the sellar region (Aalbersberg et al. 2019; Shastry et al. 2010). In the present study, we used co-registration with high-resolution MRI to optimise localisation of radiopharmaceutical uptake in the macroadenoma versus pituitary tissue. Still, maintaining a clear margin between the adenoma and pituitary is necessary to avoid activity spillover and overestimation of adenoma uptake. We therefore decided to place a circular ROI within the adenoma instead of manual delineation of the adenoma boundaries.
Partial volume effects play a role in the underestimation of radiotracer uptake in lesions smaller than two to three times the PET system’s spatial resolution (full width at half maximum) (Bettinardi et al. 2014). In our series, however, adenoma size was at least 12 mm, and consequently, the partial volume effect in our study is negligible. This may explain why we did not observe a significant correlation between adenoma size and SUVmean. It is therefore also unlikely that the PET-negative cases are false negatives due to the partial volume effect.
It is important to note that 68Ga-DOTATATE, as compared with 111In-DTPA-octreotide, has about 100 times higher affinity for SSTR2, decreased affinity for SSTR3 and similar affinity for SSTR5 (Reubi et al. 2000). In this light, the high positivity rate in our study was unexpected based on the notion that SSTR3 is the most abundantly expressed subtype in NFA (Even-Zohar and Greenman 2018; Colao et al. 2008). However, over the years, in vitro studies examining the SSTR expression in NFA specimens have produced conflicting results, pointing to either SSTR2 (Ramírez et al. 2012), SSTR3 (Gabalec et al. 2015) or SSTR5 (Fusco et al. 2012) as the dominant subtype. Possible explanations for these inconsistencies include differences in the method (detection of mRNA expression or protein, antibody specificity, membranous or cytoplasmic staining), patient selection (only gonadotropin-expressing or histopathologically diverse NFA) and the inherent heterogeneous distribution of various SSTR subtypes in NFA tissue samples. In the largest sample studied thus far, SSTR1–3 mRNA was expressed in 100% and SSTR5 mRNA in 60% of 198 specimens, using quantitative real-time RT-PCR (Gabalec et al. 2015). Nonetheless, mRNA levels do not always equal protein expression or the presence of functional receptors. This could explain the discrepancies between in vitro and in vivo results, as correctly translated, folded and transported SSTR proteins are required for ligand binding and in vivo detection.
The major advantage of 68Ga-DOTATATE PET is that it reliably visualises SSTR expression in vivo. Furthermore, assessment of 68Ga-DOTATATE uptake in NFMA may help to predict clinical response to SSTR2 preferential SSA (Colao et al. 2008).
Conclusion
We present the first report of 68Ga-DOTATATE PET performed in a series of NFMA patients, demonstrating in vivo SSTR expression in the vast majority of cases. The high positivity rate suggests the presence of functional SSTR in more NFMA patients than previously reported. This opens novel perspectives for trials with somatostatin analogues, especially if a positive 68Ga-DOTATATE PET scan is used to select patients for treatment.
Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available as the study is embedded in an ongoing clinical trial but are available from the corresponding author on reasonable request.
Abbreviations
- 111In-DTPA-octreotide:
-
Indium-111-labelled diethylenetriaminepentaacetic acid-octreotide
- 68Ga-DOTATATE:
-
Gallium-68-labelled dodecanetetraacetic acid-[Tyr3]-octreotate
- AMC:
-
Academic Medical Center (Amsterdam UMC, University of Amsterdam)
- Amsterdam UMC:
-
Amsterdam University Medical Centres
- CT:
-
Computer tomography
- LUMC:
-
Leiden University Medical Center
- MRI:
-
Magnetic resonance imaging
- NFA:
-
Non-functioning adenoma
- NFMA:
-
Non-functioning macroadenoma
- PET:
-
Positron emission tomography
- ROI:
-
Region of interest
- SPECT:
-
Single-photon emission computed tomography
- SSA:
-
Somatostatin analogue
- SSTR:
-
Somatostatin receptor
- SUV:
-
Standard uptake value
- VUmc:
-
VU University Medical Center (Amsterdam UMC, VU University)
References
Aalbersberg EA, de Wit–van der Veen BJ, Versleijen MWJ, Saveur LJ, Valk GD, Tesselaar MET et al (2019) Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation. Eur J Nucl Med Mol Imaging 46:696–703
Bai B, Bading J, Conti PS (2013) Tumor quantification in clinical positron emission tomography. Theranostics 3:787–801
Bettinardi V, Castiglioni I, De Bernardi E, Gilardi MC (2014) PET quantification: strategies for partial volume correction. Clin Transl Imaging 2:199–218
Borson-Chazot F, Houzard C, Ajzenberg C, Nocaudie M, Duet M, Mundler O et al (1997) Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide. Clin Endocrinol 47:589–598
Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S (2008) Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer 15:905–915
Even-Zohar N, Greenman Y (2018) Management of NFAs: medical treatment. Pituitary 21:168–175
Fusco A, Giampietro A, Bianchi A, Cimino V, Lugli F, Piacentini S et al (2012) Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. Pituitary 15:571–578
Gabalec F, Drastikova M, Cesak T, Netuka D, Masopust V, Machac J et al (2015) Dopamine 2 and somatostatin 1-5 receptors coexpression in clinically non-functioning pituitary adenomas. Physiol Res 64:369–377
Ramírez C, Cheng S, Vargas G, Asa SL, Ezzat S, González B et al (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab 97:1745–1751
Reubi JC, Schaer J-C, Waser B, Wenger S, Heppeler A, Schmitt JS et al (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med Mol Imaging 27:273–282
Shastry M, Kayani I, Wild D, Caplin M, Visvikis D, Gacinovic S et al (2010) Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nucl Med Commun 31:1
Acknowledgements
The authors thank the staff of the Departments of Radiology and Nuclear Medicine of the Netherlands Cancer Institute and the Amsterdam UMC location AMC for their assistance in this study, with special thanks to Bastiaan W.A. Kee (Amsterdam UMC) for the excellent support with analysis and co-registration of images, and Youssef Chahid (Amsterdam UMC) for 68Ga-DOTATATE radiosynthesis for most PET scans.
Funding
Not applicable.
Author information
Affiliations
Contributions
TB, JB, CM, MD, MS, PB and EF participated in the design of the study. MD, AP, NB, SS, RGV, PB and EF assisted with the referral and inclusion of patients. TB co-registered and analysed the images, with the assistance of CM and JB. TB collected the data, performed the statistical analyses and drafted the manuscript. JB, PB and EF helped to draft the manuscript. EF supervised the study. All authors reviewed and approved the final manuscript.
Corresponding author
Correspondence to Tessel M. Boertien.
Ethics declarations
Ethics approval and consent to participate
The study protocol was approved by the Medical Ethics Committee of the Academic Medical Centre (reference number METC 2015_103) and registered at the Netherlands Trial Register (NL5136, www.trialregister.nl/trial/5136) and EudraCT (2015-001234-22, https://eudract.ema.europa.eu/). All procedures involving human participants were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual participants included in the study.
Consent for publication
Not applicable.
Competing interests
This research is part of an investigator-initiated study with financial support from Ipsen Farmaceutica BV (the Netherlands).
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Boertien, T.M., Booij, J., Majoie, C.B.L.M. et al. 68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas. European J Hybrid Imaging 4, 4 (2020). https://doi.org/10.1186/s41824-020-0073-3
Received:
Accepted:
Published:
Keywords
- Non-functioning pituitary adenoma
- Somatostatin receptors
- 68Ga-DOTATATE
- PET/CT
- MRI co-registration
